Research programme: apoptosis stimulants - Myrexis

Drug Profile

Research programme: apoptosis stimulants - Myrexis

Alternative Names: EP128265; EP90745 series; MPI-0441138; MX90745 series

Latest Information Update: 26 Nov 2012

Price : $50

At a glance

  • Originator EpiCept Corporation
  • Developer Myrexis
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 01 Sep 2010 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 30 Jun 2010 Myriad Pharmaceuticals is now called Myrexis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top